UBS Group
AVIR icon

UBS Group’s Atea Pharmaceuticals AVIR Stock Holding History

UBS Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Sell
109,950
-82,590
-43% -$379K ﹤0.01% 5966
2025
Q4 		$687K Buy
192,540
+90,329
+88% +$287K ﹤0.01% 5875
2025
Q3 		$296K Sell
102,211
-7,213
-7% -$24.6K ﹤0.01% 6441
2025
Q2 		$394K Buy
109,424
+45,856
+72% +$137K ﹤0.01% 6209
2025
Q1 		$190K Sell
63,568
-9,345
-13% -$29.2K ﹤0.01% 6593
2024
Q4 		$244K Sell
72,913
-5,478
-7% -$18.2K ﹤0.01% 6330
2024
Q3 		$263K Buy
78,391
+6,812
+10% +$24.7K ﹤0.01% 5676
2024
Q2 		$237K Sell
71,579
-32,491
-31% -$121K ﹤0.01% 5549
2024
Q1 		$420K Sell
104,070
-3,576
-3% -$14K ﹤0.01% 5336
2023
Q4 		$328K Buy
107,646
+50,605
+89% +$153K ﹤0.01% 5431
2023
Q3 		$171K Sell
57,041
-41,823
-42% -$142K ﹤0.01% 5465
2023
Q2 		$370K Buy
98,864
+46,051
+87% +$172K ﹤0.01% 5073
2023
Q1 		$177K Sell
52,813
-22,422
-30% -$91K ﹤0.01% 5487
2022
Q4 		$362K Buy
75,235
+59,818
+388% +$303K ﹤0.01% 4969
2022
Q3 		$88K Buy
15,417
+4,166
+37% +$31.9K ﹤0.01% 5812
2022
Q2 		$80K Sell
11,251
-17,754
-61% -$121K ﹤0.01% 5586
2022
Q1 		$209K Sell
29,005
-75,716
-72% -$514K ﹤0.01% 5318
2021
Q4 		$935K Buy
104,721
+41,034
+64% +$639K ﹤0.01% 4451
2021
Q3 		$2.23M Sell
63,687
-611,422
-91% -$17M ﹤0.01% 3485
2021
Q2 		$14.5M Buy
675,109
+671,483
+18,519% +$20.2M ﹤0.01% 1734
2021
Q1 		$224K Sell
3,626
-6,944
-66% -$469K ﹤0.01% 5404
2020
Q4 		$442K Buy
+10,570
New +$341K ﹤0.01% 4693

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group's AVIR Position: Q1 2026 in Review

UBS Group reduced its Atea Pharmaceuticals (AVIR) stake by 43% in Q1 2026, selling an estimated $379K and leaving 109,950 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #5966.

UBS Group first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $14.5M in Q2 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • UBS Group held 109,950 shares of Atea Pharmaceuticals worth $592K as of Q1 2026.
  • UBS Group sold 82,590 Atea Pharmaceuticals shares in Q1 2026, an estimated $379K.
  • Atea Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5966 holding.
  • UBS Group first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's Atea Pharmaceuticals position peaked at $14.5M in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.